A handful of cash-rich pharma companies have announced billions of dollars in share buybacks in recent months, raising questions about their interest in transformative dealmaking
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Roche’s $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company. Cayman Islands-based Legacy Pharma is run by
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor. Jeff Legos, the global … Sign up
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron’s share of the degenerative eye disease market, said six-month results show its drug met
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS